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    Vitamin B6 is a water soluble vitamin and the active form, pyridoxal 
5’-phosphate (PLP), acts as a necessary cofactor for more than 100 enzymatic 
reactions. There is growing epidemiological evidence for vitamin B6 acting as a 
protective factor against cancers, inflammatory bowel disease and cardiovascular 
disease. Recent evidence suggest that inadequate intake of vitamin B6 is prevalent in 
the US and Japan. It has been suggested that the anti-tumor effect of dietary vitamin 
B6 is, at least, partially ascribed to lowering colon cell proliferation, oxidative stress, 
inflammation, angiogenesis, epithelium cell damage and DNA damage. However, the 
molecular mechanisms involved in the anti-tumor effect of vitamin B6 are not yet 
clearly understood. Previous studies have suggested that the anti-cardiovascular 
disease effect of vitamin B6 might be partially ascribed to its anti-inflammatory 
function. However, the mechanisms are still unclear. The objective of this study was 
to investigate the anti-disease function of vitamin B6 in cell culture and animal 
studies.  
    The preliminary study using DNA microarray analysis was conducted to 
examine the expression of genes in colon carcinoma HT29 cells exposed to 
pyridoxal (PL: 500 M) for 24 h. Expression of several genes relating to diseases, 
including cystatin A (CSTA), cyclin-dependent kinase inhibitor 1A (p21), 
insulin-like growth factor binding protein 1 (IGFBP1), growth arrest and 
DNA-damage-inducible beta (GADD45B), vitamin D receptor (VDR), 
DNA-damage-inducible transcript 3 (DDIT3) and NADPH oxidase 1 (NOX1), were 
altered by PL. The upregulation of mRNA expression of CSTA, p21, IGFBP1, 
GADD45B, VDR and DDIT3 (anti-disease factors), and downregulation of mRNA 
expression of NOX1 (disease promoting factor) were confirmed by real-time PCR in 
HT29 cells treated with PL (500 M) for 24 h. 
    In the first study, I mainly focused on the effect of vitamin B6 on gene and 
protein expression of IGFBP1. IGFBP1 is mainly produced in the liver and secreted 
from the liver. IGFBP1 has been reported to be a tumor suppressor via binding to 
insulin growth factors (IGFs), modulating their actions. IGFBP1 is also known to be 
a hepatoprotective factor. Expression of IGFBP1 is elevated by fasting and exercise, 
and suppressed by insulin. Recent study further suggested that IGFBP1 has a 
protective role in the development of cardiovascular disease. Thus, experiments were 
performed to examine the effect of vitamin B6 on the expression of IGFBP1 in 
hepatocarcinoma HepG2 cells. Adding PL (500 μM) markedly elevated the mRNA 
expression of IGFBP1 in HepG2 cells at 6 h, 12 h and 24 h, whereas other vitamers 
(500 μM), including pyridoxal 5’-phosphate (PLP), pyridoxine (PN) and 
pyridoxamine (PM), caused no such effect. PL caused a dose-dependent increase in 
mRNA expression of IGFBP1 in HepG2 cells. The protein expression of IGFBP1 in 
the cell lysate and culture medium was also markedly elevated in the presence of PL 
in a time-dependent manner. PL elevated the expression of p-ERK1 (active form of 
ERK1) and the p-c-Jun proteins (a down stream factor of ERK). Furthermore, the 
elevation in mRNA and protein of IGFBP1 by PL was suppressed by PD98059, an 
ERK inhibitor. Treatment of cycloheximide, a protein synthesis inhibitor, completely 
inhibited the elevation in protein expression of IGFBP1 by PL, suggesting that the 
higher protein expression of IGFBP1 induced by PL is dependent on the protein 
synthesis. Thus, the possibility of the suppressed degradation of IGFBP1 protein by 
PL treatment appears to be negated. Furthermore, PL stimulated the mRNA 
expression of IGFBP3 and IGFBP4 in a time- and dose-dependent manner in HepG2 
cells. Adding of the ERK inhibitor suppressed the stimulation of the gene expression 
of IGFBP3 and IGFBP4 by PL. These results suggest that PL can induce the 
expressions of IGFBP1, IGFBP3 and IGFBP4 in hepatoma cells via a mechanism 
involving the ERK pathway. Higher expression of these IGFBPs by vitamin B6, 
together with their inhibitory effects on cell proliferation, suggests the anti-tumor 
effect of vitamin B6 via elevating IGFBPs. 
    Growing evidence suggests that dietary vitamin B6 is linked to inhibiting 
tumorigenesis in the colon. Importantly, our group has demonstrated that high 
dietary vitamin B6 suppressed colon epithelium cell proliferation, which may 
contribute to suppressing the colon tumorigenisis by vitamin B6. However, the 
molecular mechanisms involved in this process are not yet understood. In the second 
study, the upregulation in mRNA expression of p21 was confirmed in colon 
carcinoma HT29 cells exposed to PL by real-time PCR analysis. p21 is known as 
cyclin-dependent kinase inhibitor 1, and functions as a negative regulator of cell 
cycle progression. The expression of this gene is tightly controlled by the tumor 
suppressor protein p53. p21 has been suggested to be a tumor suppressor in vitro and 
in vivo in several studies. The effect of PL on the gene expression of p21 in other cell 
lines was analyzed. The results showed that PL elevated the gene expression of p21 
in Caco2 cells, HEK293T cells and HepG2 cells. Adding PL significantly elevated 
the mRNA expression of p21 in both HT29 cells and HepG2 cells at 24 h, whereas 
other vitamers, including PLP, PN and PM, caused no such effect. In order to 
understand the mechanism of higher mRNA expression of p21 by PL, the p53 
activation was examined (the upstream factor for p21 mRNA transcription) in both 
HT29 cells and HepG2 cells. The results indicated that PL caused higher protein 
level of p-p53 (active form of p53) of whole cell lysate and nucleus in these two cell 
lines. 
    To understand the effect of vitamin B6 on the p53 activation and mRNA 
expression of p21 in vivo, two groups of mice fed with different vitamin B6 diets for 
5 weeks were investigated. Western blot analysis showed that vitamin B6 deficient 
diet caused a trend of lower protein expression of p-p53 compared with normal 
vitamin B6 diet. Real-time PCR analysis indicated that the mRNA expression of p21 
in colon was also significantly reduced by vitamin B6 deficient diet compare to that 
of the normal vitamin B6 diet. These results suggest an important role of vitamin B6 
in elevating protein of p-p53 and mRNA of p21 in the cancer cell lines and colon of 
mice. Taken together, my study implies the anti-tumor effect of vitamin B6 via 
elevating p-p53 and p21. 
    In conclusion, the first study showed that PL caused upregulation of mRNA 
expression of CYSTA, p21, IGFBP1, GADD45B, VDR and DDIT3, and 
downregulation of mRNA expression of NOX1 in HT29 cells and HepG2 cells. As 
for the expression of IGFBPs, only PL of the vitamers caused marked elevation of 
the mRNA and protein expression of IGFBP1 and mRNA expression of IGFBP3 and 
IGFBP4 in HepG2 cells. The mechanistic study suggests that PL can induce 
expression of these IGFBPs in HepG2 cells via a mechanism involving ERK 
pathway. The second study provided evidence that PL elevated the mRNA of p21 
and p-p53 protein in both HT29 cells and HepG2 cells. The significant elevation in 
the mRNA of p21 was found in the mice fed with the normal vitamin B6 diet 
compared with that of vitamin B6 deficient diet. Taken together, these findings 
suggest the novel mechanisms of the anti-disease function of vitamin B6 through the 
modulation of IGFBPs and p21.  
